WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced commercial launch of a new Sport Electrode for its innovative Quell ® Wearable Pain Relief Technology™. The new electrode has a special hydrogel designed to better hold up in situations with high humidity and

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of the initial Quell ® study in the Journal of Pain Research . The paper is titled "Fixed-Site High-Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of Chronic Low Back and Lower

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that WBC Group, LLC will be the exclusive distributor of Quell ® Wearable Pain Relief Technology ™ to chiropractors, physical therapists, physical fitness facilities and personal trainers through their MeyerDC,

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) and the Scripps Translational Science Institute (STSI) today announced a clinical study of Quell ® wearable pain relief technology in patients with cancer related pain. According to the National Cancer Institute , about 15 million

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) announced today that a CE (Conformité Européenne ) Technical File Application for Quell ® has been submitted to TŰV SŰD Product Service GmbH, which is one of the Notified Bodies responsible for reviewing and approving new

100% Drug Free, FDA Cleared Wearable for Widespread Relief from Chronic Pain WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell ® Wearable Pain Relief Technology™ will be featured at the Western Foot & Ankle Conference to be held June 23-26 in Anaheim, CA.

WALTHAM, Mass. --(BUSINESS WIRE)--   NeuroMetrix, Inc.  (Nasdaq: NURO) announced today that Quell ® Wearable Pain Relief Technology ™ is available in Canada via Amazon Canada. "Canadian consumers have been asking for easier access to Quell," said Frank McGillin, SVP and General Manager of

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell ®  Wearable Pain Relief Technology ™ , reported purchases during May 2016 of the company's common stock by its Chief Executive Officer, Dr. Shai N. Gozani ; its Chief Financial Officer, Thomas T.

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Quell ®  Wearable Pain Relief Technology ™ will be featured at SLEEP 2016, which is a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society .

WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix , Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 21,300 shares of Series D convertible preferred stock at a